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Abstract
Classic deamination mRNA changes, including cytidine to uridine (C-to-U) and adenosine
to inosine (A-to-I), are important exceptions to the central dogma and lead to significant al-
terations in gene transcripts and products. Although there are a few reports of non-classic
mRNA alterations, as yet there is no molecular explanation for these alternative changes.
Wilms Tumor 1 (WT1)mutations and variants are implicated in several diseases, including
Wilms tumor and acute myeloid leukemia (AML). We observed two alternative G-to-A
changes, namely c.1303G>A and c.1586G>A in cDNA clones and found them to be recur-
rent in a series of 21 umbilical cord blood mononuclear cell (CBMC) samples studied. Two
less conserved U-to-C changes were also observed. These alternative changes were found
to be significantly higher in non-progenitor as compared to progenitor CBMCs, while they
were found to be absent in a series of AML samples studied, indicating they are targeted,
cell type-specific mRNA editing modifications. Since APOBEC/ADAR family members are
implicated in RNA/DNA editing, we screened them by RNA-interference (RNAi) forWT1-
mRNA changes and observed near complete reversal ofWT1 c.1303G>A alteration upon
APOBEC3A (A3A) knockdown. The role of A3A in mediating this change was confirmed by
A3A overexpression in Fujioka cells, which led to a significant increase inWT1 c.1303G>A
mRNA editing. Non-progenitor CBMCs showed correspondingly higher levels of A3A-
mRNA and protein as compared to the progenitor ones. To our knowledge, this is the first
report of mRNA modifying activity for an APOBEC3 protein and implicates A3A in a novel
G-to-A form of editing. These findings open the way to further investigations into the mecha-
nisms of other potential mRNA changes, which will help to redefine the RNA editing para-
digm in both health and disease.
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Introduction
According to the central dogma, genetic information is faithfully transferred from DNA to
mRNA to protein. Classic mRNA editing in both plant and animal cells is an important excep-
tion where mRNA is altered during or after transcription. In human cells, APOBEC1 (apolipo-
protein B mRNA editing enzyme, catalytic polypeptide 1; A1) was first recognised to alter
cytidine to uridine (C-to-U) in APOB (apolipoprotein B) transcripts, changing the Gln codon
(CAA) to a nonsense codon (UAA), and leading to ApoB48 rather than ApoB100 variant[1].
ADAR1 (adenosine deaminase, RNA-specific) was then identified to modify adenosine in
double-stranded (ds-) mRNA to inosine (A-to-I), causing unwinding of the ds-mRNA[2].
Since inosine shows similar base-pairing properties to guanosine (G), it is interpreted as G by
the translation machinery as well as in vitro polymerase reactions. While APOBEC1 knockout
leads to defects which are not incompatible with development[3], ADAR1 is essential for main-
tenance of hematopoiesis[4], and its gene knockout leads to lethal hematopoietic impairment
and liver disintegration in mouse embryos[5]. Other APOBEC family members are mainly
known for their DNA-editing functions.
Both classic editing events in mammals comprising A-to-I and C-to-U alterations are medi-
ated by nucleoside deamination reactions. Although there are some reports of reverse U-to-C
[6, 7] as well as G-to-A[7, 8] alterations in mammalian transcripts, they cannot be explained by
deamination reactions. Such non-classic changes are overlooked in computational studies or
attributed to misalignment to the opposite strand[9], and many are systematically disregarded
due to coincidence with polymorphic sites. A recent study reported different types of
RNA-DNA differences (RDDs), including G-to-A and U-to-C changes in B lymphocytes[10],
apparently making the editing paradigm much more complicated. However, due to the lack of
a known molecular mechanism to effect these non-classic changes, the nature of such editing
remains uncertain.
Non-classic U-to-C mRNA editing was first reported inWT1 transcripts[6]. WT1 is a regu-
latory protein with dual tumor suppressor/oncogene activity depending on the isoforms ex-
pressed, including the Lys-Thr-Ser (KTS) variant. WT1 splicing variants with excluded
tripeptide (-KTS) mainly act as transcriptional regulators, while the isoforms retaining the tri-
peptide (+KTS) show post-transcriptional activity (reviewed in [11]). In addition,WT1muta-
tions affecting the zinc finger (ZnF) domains are implicated in Wilms tumor[12] and acute
myeloid leukemia (AML)[13]. While studying the role ofWT1 variants in AML and CBMCs,
we observed recurrent G-to-A and occasional T-to-C changes inWT1-cDNA from CBMCs.
We first demonstrated that such alternative changes were true cell type-specific mRNA modifi-
cations, rather than in vitro phenomena. Next, we hypothesized that known RNA/DNA editors
might be implicated in these modifications. Hence, we used these novel changes inWT1 as a
marker and assessed how they were affected by APOBEC/ADAR knockdown. The results were
confirmed by overexpression studies.
Materials and Methods
CBMC collection
Human umbilical cord blood samples were collected from normal deliveries in the Royal
London Hospital after obtaining written and signed informed consent, and with the project ap-
proved by the East London Research Ethics Committee. The samples were processed separately
(Cb samples), or up to five samples were pooled for some experiments (Cbp samples). Blood
was diluted using 2 volumes of phosphate buffered saline (PBS) before being layered on half
volume of Ficoll in 50 ml tubes and centrifuged at 360 X g for 30 minutes at 20°C. The middle
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buffy coat layer containing the CBMCs was transferred to a new tube and washed with PBS
containing 2% fetal bovine serum (FBS), before spinning at 300 X g for 7 minutes at 4°C. Red
cell lysis was performed using cold ammonium chloride. Viable cells were counted by Trypan
blue exclusion on a Neubauer hemocytometer.
Cell separation
Progenitor (lineage-marker negative) CBMCs were separated from non-progenitor (lineage-
marker positive) cells using the StemSep Human Progenitor Enrichment Kit (StemCell Tech-
nologies) according to the manufacturer’s protocol. Briefly, CBMCs were incubated with a
cocktail of antibodies against human hematopoietic lineage markers, followed by incubation
with a magnetic colloid. The cell suspension was then pumped through a negative selection col-
umn mounted in a magnetic stand. The progenitor CBMCs were collected at the tubing outlet,
and the non-progenitor CBMCs were separately washed through the column after removal
from the magnetic stand. Cells were cryopreserved in 10% DMSO / 90% FBS at -80°C for
later use.
AML samples
Peripheral blood or bone marrow samples were collected from AML patients attending
St Bartholomew’s Hospital, London, after obtaining written and signed informed consent. Es-
tablished myeloid cell lines THP1[14], Fujioka[15], HL60[16], and KG1[17] were obtained
from London Research Institute’s repository.
DNA and RNA extraction
Genomic DNA was extracted from 106 cells using DNeasy Blood & Tissue Kit (Qiagen) accord-
ing to manufacturer’s protocol. Total RNA was also extracted from up to 5 x 105 and 5–50 x 105
cells using RNeasy Micro and Mini Kits (Qiagen), respectively, according to manufacturer’s
protocols. All RNA samples were treated with DNase, as recommended by the manufacturer.
PCR
WT1 exon 7 was amplified using 20–50 ng of gDNA, 200 nMWs-X7f5 (see S3 Table for prim-
ers), 200 nMWs-X7r5, 200 μM dNTP mix, and 1 U Taq DNA Polymerase (Qiagen) on a PTC-
225 DNA Engine (MJ Research) for 35 cycles with annealing at 61°C.WT1 exon 9 was also
amplified according to the same protocol, but using Ws-X9f3 and Ws-X9r2 primers. The
amplicons were then gel-extracted using Qiaquick Gel Extraction Kit (Qiagen), making it
ready for cloning or direct Sanger sequencing.
RT-PCR
cDNA was made according to the SuperScript III First-Strand Synthesis protocol (Life Tech-
nologies) using up to 5 μg total RNA, 2.5 μM oligo(dT)20, and 500 μM dNTP mix.WT1-cDNA
was amplified using a mixture of 2 μl cDNA, 300 nMWs-Ex6f (see S3 Table for primers), 300
nMWs-Ex10r, 200 μM dNTP mix, and 1 U Taq DNA polymerase (Qiagen) on PTC-225 DNA
Engine (MJ Research) for 35 cycles with denaturation and annealing temperatures of 93°C and
58°C, respectively. The amplicons were then gel-purified as described above.
Quantitative RT-PCR
A3A and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels were assessed
using Taqman Gene Expression assays (Hs00377444_m1 and Hs99999905_m1, respectively;
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Life Technologies) according to manufacturer’s protocol. A3A and GAPDHmRNA levels were
assessed in triplicate. The Life Technologies 7900HT Fast Real-Time PCR System was used for
amplification, and the results were analyzed using SDS software (v2.3, Life Technologies).
gDNA and cDNA Cloning
Gel purified PCR or RT-PCR products were cloned using TOPO XL PCR Cloning Kit (Life
Technologies) according to manufacturer’s instructions. Transformed E. coli was spread on LB
agar plates at 37°C overnight. Between 30 to 50 colonies per RT-PCR product or 280 colonies
per PCR product were randomly picked and inoculated into 1 ml LB media in 96-well blocks,
and incubated in a shaker at 37°C overnight for plasmid preparation. In order to assess other
hematopoietic transcripts in CBMCs and alsoWT1-cDNA in AML cells, at least 10 colonies
were examined per sample. The plasmids were extracted using Nucleospin Robot-96 Plasmid
Core Kit (ClonTech) on a BioRobot 9600 machine (Qiagen).
Sequencing
Direct Sanger sequencing was performed using gel-purified PCR/ RT-PCR products, the same
amplification primers, and BigDye Terminator kit (v3.1, Life Technologies), for 25 cycles. The
amplified gDNA/ cDNA was analyzed using a 3730xl BioAnalyzer (Life Technologies) after
dye-exclusion with Chemagic SEQ Pure Kit on a Biomek FX machine (Beckman Coulter).
Sanger sequencing of the gDNA/ cDNA clones was performed using the same protocol, but
with miniprep plasmids and universal M13f/ M13r primers for the cycling reaction.
siRNA design
One siRNA (small-interfering RNA) was designed for each of 14 candidate genes using Dhar-
macon’s siDesign Center (www.dharmacon.com/designcenter) and two additional siRNAs for
A3A. The siRNAs were selected using the following criteria: a GC ratio of 30–64%; preferential
targeting of the open reading frame (ORF); affecting as many variants as possible; highest pre-
dicted efficiency; at least two mismatches for each of the antisense and sense strands; and low
frequency of seed region (sense nucleotides 2 to 8) matching to 3’UTRs throughout the genome
(S2 Table). Two control siRNAs were designed with no specific target in human transcriptome,
of which one was linked to Alexa-488 fluorochrome for microscopic assessment of the
transfection efficiency.
siRNA transfection
Pooled or separate CBMC samples were resuspended at a density of 5 x 105 cells /ml in 5%
FBS-IMDM (Iscove's Modified Dulbecco's Medium, Life Technologies) and incubated at 37°C
and 5% CO2 overnight. For silencing experiments, a mixture of 3 μl test or control siRNA
20 μM (Sigma-Aldrich; final concentration 100 nM), 3 μl Alx-si 20 μM (Sigma-Aldrich), and
5 μl HiPerfect Transfection Reagent (Qiagen) was added to 8 x 105 CBMCs in 109 μl 5%
FBS-IMDM in a 24-well plate and incubated at 37°C and 5% CO2 for 6 hours. Then, they were
topped up using 480 μl pre-warmed 5% FBS-IMDM and incubated as above. The plates were
examined using fluorescent microscopy for transfection efficiency after 24 hours. Efficiently
transfected samples were harvested 48 hours after the transfection, and their total RNAs ex-
tracted immediately as described above.
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Plasmid transfection
Green-fluorescent protein (GFP)-tagged A3A overexpression (RG220995) and empty
pCMV6-AC-GFP (PS100010) vectors were obtained from OriGene. Overexpression was per-
formed using the Amaxa Cell Line Nucleofector Kit V (Lonza) with 3.5ug DNA per 2 million
cells. GFP positive cells were sorted on a Cytomation MoFlo or a BD FACS Aria sorter.
Western blot analysis and protein quantitation
Protein was extracted using RIPA buffer containing protease inhibitor and DTT (Sigma-
Aldrich). Western blots were performed using a Novex Mini Cell gel tank and Novex gels (Life
Technologies), and semi-dry transfers using Hybond ECL membrane (GE Healthcare). Protein
was detected using rabbit anti-APOBEC3A (Santa Cruz Biotechnology) and mouse anti-beta-
Actin (Sigma-Aldrich), followed by HRP-conjugated goat anti-rabbit and anti-mouse second-
ary antibodies (Sigma-Aldrich), respectively. Detection was performed using ECL Plus (GE
Healthcare). Relative protein quantification was performed using Image J.
Statistical analysis
A% value at c.1303 was obtained by counting the A/G in sequenced clones and performing the
calculation 100 x A / (A + G). Fisher’s Exact test (GraphPad Prism, version 5.01) was used to
compare the A% at c.1303 between each experiment and the control, and also for alterations in
progenitor/ non-progenitor subpopulations. For association analyses, under a hypothesis of in-
dependence of changes occurring at the two sites, the count data for changes at neither, only at
site 1, only at site 2, and at both sites follow a multinomial distribution. We estimated the inde-
pendent probabilities from the observed data (i.e. total number of changes at each site relative
to total number of clones assessed) and provided the R function dmultinom with these esti-
mates to assess the probability of the observed data under this null.
Results
WT1 transcripts are subject to alternative changes
Exons 6 to 10 ofWT1-cDNA (Fig. 1A), corresponding to ZnF1 to ZnF4 domains, were cloned
and sequenced from a pooled sample of human CBMCs, representative of hematopoietic cells,
to investigate potential mRNA variants affecting WT1 function. Differences were observed at
single-nucleotide cDNA sites, as compared to the EST (Expressed Sequence Tag) and RefSeq
databases, and paired DNA sequence (Fig. 1B). These differences included a classic A-to-G
change at c.1528 (NM_024426.3), novel T-to-C alterations at c.1388 and c.1402, and also novel
G-to-A changes at c.1303 and c.1586, among them two modifying the amino acid sequence of
the WT1 (c.1388T>C and c.1586G>A resulting in p.C330R and p.D396N, respectively). The
c.1303 position corresponds to a common A/G polymorphic site (rs16754; g.39137,
NG_009272.1), but there was no genomic A allele in the sample. We refer to these potential
G-to-A and U-to-C mRNA alterations as alternative mRNA changes, to distinguish them from
classic deamination ones.
BLAST analysis of theWT1 amplicon showed little homology to any other known ESTs, in-
cluding antisense ESTs andWT1 antisense (NCBI Gene ID: 51352). This excluded the possibil-
ity of the classic C-to-U and A-to-G alterations in an antisense strand as a cause of observed
G-to-A and U-to-C changes, respectively. We tested the possibility of minor primary genomic
changes samples with prominent c.1586G>A alteration, which did not show any genomic
DNA (gDNA) changes in 280 copies. In order to validate the alternative modifications in a
larger series of CBMCs, we later examined the sameWT1 region using Sanger sequencing of
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paired gDNA-cDNA from a series of 21 CBMC samples (S1 Table). Sixteen samples showed
prominent G-to-A change at c.1586 (Fig. 1C). Among nine samples with an informative AG
genotype at rs16754 (corresponding to c.1303), eight showed an exclusive or predominant A in
the cDNA (Fig. 1D; cb11). All nine samples with AA genotype showed just A at cDNA level,
Fig 1. Identification and validation of alternativeWT1mRNA changes. (A)WT1 gene and the 400 bp
cDNA amplicon between exons 6 and 10, as indicated by arrows. (B)WT1-cDNA clonal changes in a pool of
CBMC cells are shown, with one aligned chromatogram expanded and paired gDNA sequence. In addition to
one classic A-to-G change at c.1528, two alternative G-to-A alterations are seen at c.1303 and c.1586, and
two alternative T-to-C changes can also be seen at c.1388 and c.1402. (C) Major G-to-A changes at c.1586 in
four samples, with no A allele in paired gDNA. (D) Major G-to-A alterations at c.1303 (common A/G SNP site)
in three heterozygous CBMC samples (cb11, cb19, and cb20), and nearly complete G-to-A change in one
homozygous GG one (cb17). (E) Partial T-to-C (U-to-C in mRNA) changes at c.1388 and c.1402 in one
sample. Altered sites are indicated by arrows in both gDNA and cDNA chromatograms.
doi:10.1371/journal.pone.0120089.g001
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and more importantly, prominent A was found in the cDNA of three homozygous GG samples
(Fig. 1D; cb17), which excluded the allele-specific gene expression as a potential implicated
mechanism. Overall, both c.1303 and c.1586 target sites showed variable levels of G-to-A
change in about two thirds of the informative samples studied (Fig. 1C, D). Moreover, two
CBMC samples showed additional alternative c.1388T>C and c.1402T>C changes (Fig. 1E).
These alternative mRNA changes therefore appear to be recurrent in CBMCs.
WT1mRNA alternative changes show a cell type-specific pattern
To test the variability of these changes among different cell types, we examined the cDNA from
eight CBMC samples sorted into progenitor and non-progenitor subpopulations. These sam-
ples showed grossly increased alternative changes in non-progenitor compared to progenitor
CBMCs at c.1303G or c.1586G (Fig. 2A-C), which was subsequently confirmed by Sanger se-
quencing of the cDNA clones (Fig. 2D). Furthermore, an assessment of a series of 19 leukemic
samples by cloning did not show any repeating G-to-A mRNA changes at c.1586 (S1 Fig.).
There was also no repeating G-to-A change at c.1303 in those samples with informative hetero-
zygous genotypes. The fact that observerd changes repeated at high levels at particular sites and
in a sample-specific manner (RNA vs. DNA, CBMC vs. leukemic cell, non-progenitor vs.
Fig 2. Differential mRNA changes in CBMC progenitor and non-progenitor subpopulations. (A) Sanger sequencing ofWT1-cDNA in subpopulations of
cb44 shows that G-to-A alteration at c.1303 is grossly higher in non-progenitor as compared to progenitor subpopulation. G-to-A alteration at both c.1303 (B)
and c.1586 (C) were also found to be higher in the non-progenitor subpopulation of cb47 sample, as compared to the progenitor one. (D) Sequencing of the
WT1-cDNA clones in cb47 subpopulations confirms the differential changes at c.1303 and c.1586, and also shows a minor T-to-C change at c.1368 which is
significantly higher in non-progenitor as compared to the progenitor subpopulation. ** P< 0.01. *** P< 0.001.
doi:10.1371/journal.pone.0120089.g002
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progenitor cell) essentially excluded the implication of technical errors inherent to Taq poly-
merase and reverse transciptase enzymes in PCR, RT-PCR, and sequencing reactions. The
presence of separate clones in clonal sequencing further excluded the sequencing error as a
cause of the observed alterations.
A3A knock-down leads to nearly complete reversal ofWT1 c.1303G>A
change
Clonal analysis ofWT1-mRNA alterations in CBMCs identified two novel classic (1618A>G)
and alternative (1586G>A) changes to be significantly associated with canonical KTS splicing
variants (Fig. 3), affecting protein sequence and function[18]. WT1 splicing variants retaining
the KTS tripeptide bind preferentially to RNA and perform mRNA processing roles, while iso-
forms with excluded KTS bind preferentially to DNA and regulate transcription. Moreover, we
observed a pattern of associated alternative-classic events. For example, c.1388T>C changes
coincided (i.e. were in cis) with c.1528A>G ones (P = 0.0006; Fig. 1B) in one sample. We asked
whether this close cis position suggested a role for classic mRNA/DNA editors in alternative
editing. Therefore, we first screened all APOBEC/ADAR genes using one specific siRNA per
gene (S2 Table). A pool of CBMCs was transfected using different siRNAs andWT1-cDNA
clones were sequenced to assess G-to-A changes as a marker for RNAi effect. The G-to-A alter-
ation was found to be conserved only at c.1303 in the negative control samples, though a low
level G-to-A change (<10%) was also seen at c.1644 in two control samples. Moreover, some
non-conserved G-to-A alterations were also seen in knockdown experiments, including those
at c.1581 using A3G-si (13%) and at c.1586 using A3C-si (88%) (S2 Fig.). Hence, those siRNAs
with less than 10% G-to-A alteration at c.1303 (Adar1-si, A3A-si1, and A3H-si) or other non-
conserved sites (A3A-si1, A3B-si, A3D-si, and A3F-si) were selected for further experiments.
In follow-up experiments testing these six candidate genes, A3A-si1 resulted in nearly complete
reversal of the c.1303G>A change compared to the control (Fig. 4A), with no G-to-A alter-
ations at non-conserved sites.
In order to confirm that the observed RNAi effects were A3A-specific, we knocked down
the gene using two additional specific siRNAs, alongside A3A-si1. Assessment of A3AmRNA
level in the A3A-silenced CBMC samples showed 86% to 98% silencing efficiency for the tested
A3A-siRNAs (Fig. 4B). Phenotypic analysis ofWT1-cDNA clones demonstrated a correlated
reduction of c.1303G>A alteration as compared to the control (Fig. 4C, D). We also examined
the A3A protein level and A% at c.1303 in four myeloid cell lines which were heterozygous at
rs16754. This showed a low A% in those cell lines with a relatively low A3A level (THP1 and
Fujioka) and a high A% in those with a relatively high A3A level (HL60 and KG1) (S2 Fig.).
A3A over-expression is associated with significant increase inWT1
c.1303G>A change
In order to exclude potential RNAi off-target effects, A3A was transiently over-expressed in the
Fujioka cell line and the impact on mRNA editing examined. Basal A3AmRNA (Fig. 5A) and
protein levels (Fig. 5B) increased significantly 48 hours after A3A transfection, which was associ-
ated with more than 1.5 fold increase in A% (from 36% to 54.5%; P = 0.015) at c.1303 (Fig. 5C).
A3A expression is differentially higher in non-progenitor as compared to
progenitor CBMCs
We finally tested whether the A3A levels correlated with the pattern of differential editing
observed in CBMC populations. Assessment of A3AmRNA level among progenitor and
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non-progenitor cell populations showed a two-order higher level in the latter. Of note, the
A3A/GAPDHmRNA ratio was between 2.0 x 10-3 and 36 x 10-3 in fresh non-progenitor
CBMC subpopulations constituting more than 99% of the CBMCs, while it was just 1.4 x 10-5
to 54 x 10-5 in paired progenitor CBMC subpopulations (Fig. 6). A similar but less prominent
difference was also seen in A3A protein level (Fig. 6B, C).
Fig 3. Association of mRNA changes with canonicalWT1 variants. (A) Sanger sequencing of theWT1 cDNA clones shows that all classic c.1618A>G
alterations are in cis with canonical-KTS isoforms. (B) All alternative c.1586G>AmRNA changes are in cis with functionally relevant +KTS variants.
*** P< 0.001.
doi:10.1371/journal.pone.0120089.g003
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Discussion
Non-classic G-to-A mRNA changes were first reported inHNRNPK (heterogeneous nuclear ri-
bonucleoprotein K) transcripts in both malignant and normal colorectal samples[8], but later
were also seen alongside non-classic U-to-C alterations in brain cell TPH2 (tryptophan hy-
droxylase 2) transcripts[7]. G-to-A RNA editing has also been recently identified in the mush-
room Ganoderma lucidum by RNA-sequencing[19]. Transamination and transglycosylation
mechanisms have been proposed for plant U-to-C editing events in mitochondrial transcripts
[20]. However, G-to-A change is probably more complicated, as G and A differ in two groups
and no single reaction can interconvert them. Without a known mechanism, such changes are
currently overlooked in computational studies or attributed to misalignment to the opposite
strand[9], and many are systematically disregarded due to coincidence with polymorphic sites.
A recent whole transcriptome study claimed to find widespread RNA-DNA differences
(RDDs)[10], including G-to-A and U-to-C changes. However, no apparent correlations with
ADAR1 expression levels were identified, and hence none of the “RDDs” could be attributed to
a known regulated mRNA editing mechanism. Moreover, most “RDDs” were undermined
later and attributed to misalignment of short sequencing reads to paralogous genomic sites[21]
and systematic technical errors[22, 23].
Fig 4. Screen of candidate genes by the ability of targeted siRNAs to reverse c.1303G>A alteration in CBMC samples. (A) Six selected genes were
screened by specific siRNAs, and the resultant A% values at c.1303 were calculated from theWT1 cDNA clones sequenced. A3A-si1 resulted in nearly
complete reversal of c.1303G>A change, with no evidence of G-to-A alterations elsewhere. Values indicate the mean +/- SEM. (B) Silencing efficiencies of
different A3A-siRNAs were assessed by Taqman gene expression assay in CBMCs. (C) Phenotypic analysis of corresponding A3A-silenced CBMCs using
Sanger sequencing of theWT1-cDNA shows a virtually complete reversal of c.1303G>A change by A3A-si1 and A3A-si2, and a partial reversal by A3A-si3.
(D) Quantification of the results in (C) above, as determined by Sanger sequencing of theWT1-cDNA clones, confirming qualitative data. *** P< 0.001.
doi:10.1371/journal.pone.0120089.g004
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Herein we report novel G-to-A mRNA changes inWT1 transcripts at c.1303 and c.1586,
which are of potential functional significance. The former corresponds to polymorphic site
rs16754, which is a located in a hotspot for mostWT1mutations in AML[13], and is also im-
plicated in AML risk andWT1 expression[24]. Moreover, germline and somatic mutations cor-
responding to c.1586G>A are implicated in Wilms tumor[12] and poor risk in AML[13],
respectively, although it is reported to be polymorphic (rs28941778). We essentially excluded
the possibility of antisense C-to-U changes mimicking sense G-to-A changes, and also minor
DNA changes leading to prominent mRNA alterations. These alterations were found to be
cell-type specific. For instance, they were differentially more prominent in nonprogenitor as
compared to progenitor CBMCs. Although these cell type-specific differences indicate that al-
ternative mRNA changes in CBMCs result from true biological alterations rather than an in
vitro phenomenon, there is yet no known enzyme performing these novel changes.
Currently, APOBEC1 (A1), which classically deaminates cytidine to uridine (C-to-U), is the
only known mRNA editor among APOBEC/AID family[1], with some DNAmodifying activity
when overexpressed[25]. Other family members including APOBEC3 proteins are mainly
known for their single-stranded DNA (ssDNA) editing functions[26]. However, A3A has been
recently reported to show even higher affinity to ssRNA than ssDNA[27]. Among the ADAR
Fig 5. Validation of the role of A3A in c.1303G>A change using gene overexpression. (A) A3A/106GAPDHmRNA as assessed by Taqman gene
expression assay in Fujioka/P31 cells 48 hours after transfection by A3A-GFP plasmid, as compared to the control vector. (B) Western Blot analysis of
Fujioka cells transfected with control or A3A-GFP vector, showing exogenous GFP-tagged A3A, in addition to endogenous A3A. (C) Phenotypic analysis
shows a modest effect of A3A overexpression in the induction of c.1303G>A change (i.e. increasing A% at c.1303) in Fujioka cells, as determined by Sanger
sequencing of theWT1-cDNA clones. Values indicate the mean +/- SEM. * P< 0.05.
doi:10.1371/journal.pone.0120089.g005
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family, double-stranded mRNA editing activity is known for ADAR1[2] and ADAR2[28],
which alter adenosine to inosine (A-to-I) with the inosine interpreted as guanosine.
Our clonal analysis ofWT1-mRNA alterations revealed a pattern of associated alternative-
classic events, including mutual cis G-to-A and C-to-U changes (S4 Fig.)(P = 2.6 x 10-7).
Hence, we hypothesized that this cis position might suggest a role for classic mRNA/DNA ed-
itors in alternative editing. RNAi screening of the APOBEC/ADAR genes suggested A3A as
the potentially implicated gene, and repeat experiments using two additional A3A-siRNAs
led to similar results. These results were further tested by A3A overexpression in Fujioka
cells, with relatively low A3A expression and informative AG genotype at c.1303, which led
to a significant 1.5 fold increase in A% at that site. These findings confirm that the G-to-A
class of alternative mRNA editing is specifically mediated by an A3A-dependent mechanism.
However, the modest increase in G-to-A editing after A3A overexpression despite its almost
Fig 6. Differential expression of A3AmRNA in progenitor as compared to non-progenitor CBMCs. (A)
Six CBMC samples were sorted into progenitor and non-progenitor cells, and A3AmRNA expression was
assessed and normalized toGAPDHmRNA level. A3A expression in six pairs of samples was on average
228 (SD = 298) fold higher in non-progenitors as compared to progenitors, corresponding to differential
G-to-A editing in these populations. (B) Three pairs of pooled CBMC samples were sorted into progenitor and
non-progenitor subpopulations and examined for A3A level, showing higher levels in non-progenitors. (C)
Quantitation of the A3AWestern blot bands normalized to beta-Actin, confirming higher A3A levels in non-
progenitor cells.
doi:10.1371/journal.pone.0120089.g006
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complete reversal in RNAi studies may suggest a role for potential cofactors, as required by
deaminases[29, 30].
This novel function raises a serious question that how a known deaminase, A3A, can be im-
plicated in a non-deamination type G-to-A change. The fact that alternative changes were
found to be associated with classic alterations, including mutual G-to-A and C-to-U changes
(S4 Fig.), may suggest the involvement of a single common or two linked mechanisms for cyto-
sine deamination and G-to-A change. On the other hand, the aminated form of G (2,6-diami-
nopurine) has been found to mimic A based on the base-pairing properties[31]. Hence, it can
be assumed that the amine group resulted from C-to-U deamination or 5-methylcytidine de-
amination[32, 33] is shuttled to a linked reaction, altering G to 2,6-diaminopurine, mimicking
A (S5 Fig.). However, the implication of base exchange (transglycosylation)[34] or nucleotide
replacement can not be excluded in G-to-A alteration.
A3A has been found by previous studies to be highly expressed in monocytes/macrophages
[35] and peripheral blood mononuclear cells[36]. Our results show that there is also a differen-
tial A3A expression in non-progenitor CBMCs (including monocytes/ macrophages) as com-
pared to progenitors. This was in line with differential G-to-A editing activity observed in
mentioned subpopulations (Fig. 2), further supporting the role of physiological levels of A3A
in alternative mRNA editing.
While the human APOBEC3 (A3) family, consisting of seven proteins with one or two cytidi-
nedeaminase (CDA) domains[37], have been characterized in many respects, this is the first re-
port of an mRNA-editing function of A3A to our knowledge. Previously, A3 proteins have been
shown to have selective antiviral activity against a range of viruses[38], constituting an innate
barrier to viral nucleic acids[39]. More specifically, monodomain A3A passively enters the nu-
cleus[40], restricts various ssDNA elements including 12retroviruses[41] and endogenous retro-
elements LINE-1 and Alu[40, 42], and removes foreign DNA[35]. Intriguingly, A3A was found
to be an efficient 5-methylcytosine deaminase[43, 44], a process which is probably implicated in
DNA demethylation[43]. Finally, ectopic A3A expression has been found to cause cell cycle ar-
rest by inducing genomic hypermutation[32] and the DNA damage response (DDR)[45].
This novel function of A3A as a dual DNA-mRNAmodifier raises broader questions of the
role of mRNA editing, and specifically the role of A3A, in cancer. The fact that A3A induces
particular changes inWT1mRNA which correspond to driver cancer mutations suggests a po-
tential role for this novel modification in cancer mutagenesis. In fact, in a recent global study
assessing 14 different cancer types, A3B and A3A expression was found to be significantly
higher in those samples with an APOBEC mutation type, particularly in breast cancer samples
[46]. Follow-up screening of the APOBEC family showed A3B and A3A expression levels cor-
related to the number of APOBEC mutations among different cancers studied[46). Moreover,
another recent study found APOBEC mutational signature prevalent across 16 hematological
and non-hematological malignancies[47]. Functional studies support this hypermutating effect
of the A3B/A3A in breast cancer[48]. These studies suggest a significant role for A3A in cancer
mutagenesis. However, whether this mutagenic activity is an off-target effect of a physiological
role like viral restriction or alternative mRNA editing remains to be determined.
In summary, this study confirms the existence of two non-classic forms of mRNA editing in
human, comprising G-to-A and U-to-C changes, using targeted Sanger sequencing rather than
next-generation sequencing with its inherent potential for errors due to misalignment. These
changes are likely to be of functional consequence in view of their cell specific nature, and in
the case of G-to-A changes, their association with canonicalWT1 variants. More importantly,
the G-to-A editing was specifically mediated by A3A, which to our knowledge, is the first re-
port of a mechanism for alternative mRNA editing and furthermore of a function that has not
previously been described for any of the APOBEC3 proteins. The implication of A3A in both
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mRNA and DNA alterations and its apparent up-regulation in different cancers raises the pos-
sibility that aberrations in alternative mRNA editing are involved in cancers. This is not only
an intriguing question, but also a potential target for therapy. Moreover, our work demon-
strates an approach to identify genes which mediate other potential novel RNA changes de-
tected by modern high-throughput approaches. Finally, this study provides evidence against
exclusion of the potential RNA editing sites which are simply coinciding with polymorphic
sites in high-throughput sequencing studies.
Supporting Information
S1 Fig. Lack ofWT1 G-to-A changes at c.1586 in four representative AML samples. Nine-
teen AML samples were examined using Sanger sequencing of theWT1-cDNA clones, and the
chromatograms were aligned and examined for potential changes at c.1586, which did not
show any alterations.
(TIF)
S2 Fig. Non-conserved G-to-A alterations associated with knockdown experiments. Knock-
down experiments of the candidate genes were associated with some G-to-A alterations at
non-conserved sites which were not observed in the control experiments, including changes at
c.1581 (A) and c.1586 (B) associated with A3G-si and A3C-si, respectively.
(TIF)
S3 Fig. Correlation of A% at c.1303 with A3A protein level in myeloid cell lines. A. A% of
at c.1303 in four myeloid cell lines as determined by clonal sequencing of theWT1 transcripts.
B. Expression levels of A3A in corresponding myeloid cell lines compared to b-Actin as deter-
mined by Western blotting.
(TIF)
S4 Fig.WT1-cDNA changes in CBMCs showing a pattern of associated alternative-classic
events. Sanger sequencing chromatograms of theWT1-cDNA clones are aligned and examined
for the changes occurring in the same clones, i.e. in cis, with one altered chromatogram
expanded for each of the associated events. Statistically significant associations are found
for c.1388U>C and c.1528A>G (A), as well as c.1505C>U and c.1609G>A (B and C).
 P< 0.001.
(TIF)
S5 Fig. Models for classic and alternative mRNA changes. Classic mRNA editing is explained
by deamination reactions converting C to U (A) and A to I, which mimics G (B), while pro-
posed alternative mRNA editing model involves amination reactions converting U to C (C)
and G to D, mimicking A (D). Each edited base is shown with its paired base.
(TIF)
S1 Table. Summary of G-to-A mRNA changes in 21 CBMC samples at c.1303 and c.1586
positions, as identified by Sanger sequencing of paired DNA-cDNAs. Gross G-to-A changes
were seen in seven informative samples at c.1303 (underlined), including three homozygous
GG samples (cb5, cb17, and cb21) with prominent A at c.1303, not explained by imbalanced al-
lele expression. Sixteen samples showed prominent A at c.1586 (underlined). Overall, 17 sam-
ples showed G-to-A change at c.1303 and/or c.1586.  Samples with additional T-to-C
alterations at c.1388 and c.1402.
(PDF)
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S2 Table. Characteristics of the siRNAs used for screening of the implicated gene in alter-
native G-to-A mRNA editing.
(PDF)
S3 Table. Characteristics of the primers used for amplification ofWT1-cDNA and DNA.
(PDF)
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